StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Equities research analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report issued on Thursday. The firm set a “sell” rating on the stock.

InspireMD Trading Up 6.0 %

Shares of InspireMD stock opened at $2.13 on Thursday. The company has a market cap of $49.84 million, a price-to-earnings ratio of -1.97 and a beta of 0.92. InspireMD has a 1 year low of $1.29 and a 1 year high of $3.85. The company’s fifty day simple moving average is $2.30 and its 200-day simple moving average is $2.62.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 320.97% and a negative return on equity of 55.71%. The business had revenue of $1.76 million during the quarter, compared to analyst estimates of $1.65 million. During the same quarter in the prior year, the business earned ($0.60) earnings per share. As a group, research analysts forecast that InspireMD will post -0.61 earnings per share for the current fiscal year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. McKinley Carter Wealth Services Inc. purchased a new stake in InspireMD, Inc. (NYSE:NSPR) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $28,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.